As the biotech industry shows renewed strength with rising stock prices and growing deal values, thousands of biotech industry leaders, investors, and innovators will gather in San Francisco in January for the annual Biotech Showcase. The event, which runs concurrently with the J.P. Morgan Healthcare Conference, has become an essential gathering place for emerging companies seeking visibility, funding, and deals. In addition to a packed agenda over three days, the conference will host 7,000 meetings between biotech companies and potential investors and partners. We spoke to Sara Demy, founder and CEO of Demy-Colton — which co-produces the Biotech Showcase with the EBD Group — about what’s in store at this year’s event, the large number of partnering meetings that are scheduled, and what participants can do to get the most out of the conference.
All content for The Big4Bio Podcast is the property of Big4Bio and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
As the biotech industry shows renewed strength with rising stock prices and growing deal values, thousands of biotech industry leaders, investors, and innovators will gather in San Francisco in January for the annual Biotech Showcase. The event, which runs concurrently with the J.P. Morgan Healthcare Conference, has become an essential gathering place for emerging companies seeking visibility, funding, and deals. In addition to a packed agenda over three days, the conference will host 7,000 meetings between biotech companies and potential investors and partners. We spoke to Sara Demy, founder and CEO of Demy-Colton — which co-produces the Biotech Showcase with the EBD Group — about what’s in store at this year’s event, the large number of partnering meetings that are scheduled, and what participants can do to get the most out of the conference.
Overcoming Neuroscience Challenges Using Complex Cell Models
The Big4Bio Podcast
15 minutes 33 seconds
1 year ago
Overcoming Neuroscience Challenges Using Complex Cell Models
One of the challenges for drug discovery for new therapies to treat neurological conditions has been the need for better models of the various cells within the human brain and the interaction between different cell types. Charles River Laboratories, through a partnership with Bit Bio, has been able to access a consistent and scalable supply of a variety of induced pluripotent stem cell-derived human brain cells that have enabled the development of multi-cell cultures that can model various neurological diseases. We spoke to Malika Bsibsi, research leader at Charles River Laboratories International, about the challenges of developing treatments for neurological diseases, the limitations of animal models and single cell type cultures, and how this new approach promises to improve drug discovery in what has been a difficult area for therapeutic developers.
The Big4Bio Podcast
As the biotech industry shows renewed strength with rising stock prices and growing deal values, thousands of biotech industry leaders, investors, and innovators will gather in San Francisco in January for the annual Biotech Showcase. The event, which runs concurrently with the J.P. Morgan Healthcare Conference, has become an essential gathering place for emerging companies seeking visibility, funding, and deals. In addition to a packed agenda over three days, the conference will host 7,000 meetings between biotech companies and potential investors and partners. We spoke to Sara Demy, founder and CEO of Demy-Colton — which co-produces the Biotech Showcase with the EBD Group — about what’s in store at this year’s event, the large number of partnering meetings that are scheduled, and what participants can do to get the most out of the conference.
